AMGN

Amgen
D

AMGN

Arincen67/100B

Amgen income statement 1985–2026

38.93B USD over the last twelve months, and 36.74B USD in fiscal year 2025.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
30 Sept 2026
FY2025
31 Dec 2025
FY2024
31 Dec 2024
FY2023
31 Dec 2023
FY2022
31 Dec 2022
FY2021
31 Dec 2021
FY2020
31 Dec 2020
FY2019
31 Dec 2019
FY2018
31 Dec 2018
FY2017
31 Dec 2017
FY2016
31 Dec 2016
Revenue
38.93B36.74B33.42B28.19B26.32B25.98B25.42B23.36B23.75B22.85B22.99B
Revenue growth
+8.27%+9.92%+18.57%+7.09%+1.32%+2.18%+8.83%-1.62%+3.93%-0.62%+6.14%
Cost of revenue
10.13B10.73B12.86B8.42B6.41B6.45B6.16B4.36B4.10B4.07B4.16B
Gross profit
28.80B26.01B20.57B19.78B19.92B19.53B19.27B19.01B19.65B18.78B18.83B
Gross margin
73.97%70.80%61.53%70.15%75.66%75.16%75.77%81.35%82.73%82.19%81.90%
Research and development
7.85B6.97B5.96B4.78B4.43B6.32B4.21B4.12B3.74B3.56B3.84B
Selling, general and administrative
6.96B7.05B7.10B6.18B5.41B5.37B5.73B5.15B5.33B4.87B5.06B
Operating expenses
16.19B16.93B13.31B11.84B10.35B11.89B10.13B9.33B9.38B8.81B9.04B
12.61B9.08B7.26B7.90B9.57B7.64B9.14B9.67B10.26B9.97B9.79B
Operating income growth
+45.63%+25.10%-8.09%-17.45%+25.23%-16.41%-5.53%-5.74%+2.91%+1.83%+15.63%
Operating margin
32.39%24.71%21.71%28.01%36.34%29.40%35.95%41.41%43.22%43.65%42.60%
Interest income
———————587.00M674.00M928.00M629.00M
Interest expense
2.64B2.76B3.16B2.88B1.41B1.20B1.26B1.29B1.39B1.30B1.26B
Other non-operating income
-2.78B-1.70B-2.65B-42.00M-2.22B-938.00M-1.01B-536.00M-718.00M-376.00M-631.00M
Pretax income
11.05B8.98B4.61B7.86B7.35B6.70B8.13B9.14B9.55B9.60B9.16B
Income tax
1.66B1.27B519.00M1.14B794.00M808.00M869.00M1.30B1.15B7.62B1.44B
Effective tax rate
15.03%14.09%11.26%14.49%10.81%12.06%10.68%14.18%12.06%79.38%15.73%
9.39B7.71B4.09B6.72B6.55B5.89B7.26B7.84B8.39B1.98B7.72B
Net income growth
+34.06%+88.53%-39.11%+2.52%+11.18%-18.87%-7.37%-6.58%+324.15%-74.37%+11.28%
Net margin
24.12%20.99%12.24%23.83%24.89%22.68%28.57%33.57%35.35%8.66%33.59%
Basic shares
540.00M538.00M541.00M535.00M538.00M570.00M586.00M605.00M661.00M731.00M748.00M
Diluted shares
544.25M542.00M541.00M538.00M541.00M573.00M590.00M609.00M665.00M735.00M754.00M
Change in diluted shares
+0.51%+0.18%+0.56%-0.55%-5.58%-2.88%-3.12%-8.42%-9.52%-2.52%-1.57%
EPS (basic)
17.3814.337.6212.5612.1810.3412.4012.9612.702.7110.32
EPS (diluted)
17.2414.237.5612.4912.1110.2812.3112.8812.622.6910.24
EPS growth
+33.23%+88.23%-39.47%+3.14%+17.80%-16.49%-4.43%+2.06%+369.15%-73.73%+13.02%
Dividends per share
9.949.529.008.527.767.046.405.805.284.604.00
Dividend growth
+5.86%+5.78%+5.63%+9.79%+10.23%+10.00%+10.34%+9.85%+14.78%+15.00%+26.58%
EBITDA
18.17B16.90B13.36B14.80B12.17B11.30B13.00B12.63B12.88B12.86B12.53B
EBITDA margin
46.67%45.99%39.96%52.50%46.23%43.48%51.12%54.08%54.25%56.27%54.49%
EBIT
13.69B11.73B7.76B10.73B8.75B7.90B9.40B10.43B10.94B10.90B10.42B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Figures underlined with dots are from the company's SEC filings, where our data provider's differ.

Common questions about Amgen's income statement

Source: Financial Modeling PrepVerified against SEC filings